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the Pharmacist in Providing Pharmaceutical Care as Part
of an Integrated Disease Management Approach
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ABSTRACT
During the past decade, the profession of pharmacy has changed dramatically. The Doctor of
Pharmacy degree has replaced the Bachelor of Science degree as the first professional degree
offered at most accredited U.S. pharmacy schools. Advanced clinical training is now a main-
stay of pharmacy training, and this has enabled pharmacists to contribute to disease man-
agement efforts. In addition, technological improvements in prescription processing have af-
forded pharmacists more time to participate in disease management activities. This paper
describes how the role of the pharmacist has changed and reviews the results of programs in-
volving pharmacists as disease management providers in the areas of asthma, hypertension,




THE PROFESSION OF PHARMACY is continuingto undergo a dramatic shift in focus from
product dispensing to patient care. As tech-
nology advances to assume the task of dis-
pensing, pharmacists are given the opportu-
nity to concentrate on providing cognitive
services for patients. With more advanced
training, pharmacists have become a more in-
tegral part of the health care delivery team. The
challenge is then for pharmacists to demon-
strate their value in these alternative roles. As
a result of this change, the Doctor of Pharmacy
(Pharm.D.) degree is now the first professional
degree attainable at all U.S. pharmacy schools
but one.1 The Pharm.D. degree requires ad-
vanced clinical training through course work
as well as experiential rotations.
Over the past few years, the disease man-
agement movement has driven health care to-
ward a more outcomes driven approach to
care. Disease management (DM) has been de-
fined as a “systematic management tool ap-
plied to specific diseases with an emphasis on
prevention and ‘Best Practices’ to provide high-
quality care at a reasonable cost with an ongo-
ing process of monitoring and continuous im-
provement.”2
The growth of DM paralleled the growth of
managed care delivery systems. The types of
organizations that currently offer DM services
1Office of Health Policy and Clinical Outcomes, Thomas Jefferson University, Philadelphia, Pennsylvania.
2Neuroscience Scientific Operations, Novartis Pharmaceuticals, East Hanover, New Jersey.
3Cardiovascular Marketing, Novartis Pharmaceuticals, East Hanover, New Jersey.
4College of Pharmacy, Rutgers University, Piscataway, New Jersey.
now encompass virtually every stakeholder in
the provision of healthcare. Although manag-
ing disease has always been a part of medical
care, structured DM programs did not take
hold until the early 1990s. Managed care 
organizations (MCOs), hospitals, and clinics
are considered to be the originators of this
movement and were later joined by pharma-
ceutical companies, pharmacy benefit man-
agers (PBMs), large employers, and DM com-
panies (Fig. 1). More recently, the healthcare
industry has witnessed a surge of interest in
DM among other organizations, such as device
and laboratory companies, medical product
wholesalers and distributors, physician groups,
physician service organizations (PSOs), spe-
cialty (carveout) providers, and community
pharmacies.
Pharmacists have been involved in the de-
velopment and implementation of many DM
programs in existence today. Some have con-
tributed to the development and implementa-
tion of DM initiatives in settings that are not
directly involved in patient care (PBMs, phar-
maceutical companies), whereas others have
participated in both the development and im-
plementation in settings that do involve direct
interaction with patients (MCOs, long-term
care facilities, hospitals, home healthcare pro-
viders, integrated delivery systems, and com-
munity pharmacies).
THE EXPANSION OF PHARMACIST-
PRACTICED DISEASE MANAGEMENT
The origin of pharmacist involvement in
DM can be traced back to the inpatient set-
ting. In an effort to demonstrate their value,
clinical pharmacists began recording and
tracking pharmacy interventions. During this
early phase, pharmacist intervention was con-
sidered reactive, rather than proactive. That 
is, the bulk of interventions focused on cor-
recting existing problems with drug therapy,
such as eliminating drug interactions, as op-
posed to establishing systems to prevent prob-
lems.
Prior to the widespread use of the term
“disease management,” the concept of phar-
maceutical care was introduced.3 Pharmaceu-
tical care focuses on enhancing care for indi-
vidual patients. Pharmaceutical care was
defined as “the responsible provision of drug
therapy for the purpose of achieving definite
outcomes that improve a patient’s quality of
life.”3 In practicing pharmaceutical care, a
pharmacist is expected to assume greater re-
sponsibility for patients’ medication-related
outcomes.4
The extent to which pharmacists practice
pharmaceutical care is highly variable. For ex-
ample, a 1996 study of Virginia pharmacists5
found that community pharmacists who prac-
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FIG. 1. Influence of the growth of managed care on the types of organizations participating in disease management.
ticed pharmacy in independently owned phar-
macies in rural Virginia and had a good rap-
port with patients and local physicians were
more likely to deliver pharmaceutical care. In
addition, prescription volume of greater than
150 prescriptions per day appeared to limit a
pharmacist’s ability to engage in pharmaceuti-
cal care. Although there may be important ge-
ographical differences, the findings from this
study suggest that some higher volume retail
chains were less likely to provide pharmaceu-
tical care. However, technological advance-
ments that have expedited the script process-
ing may limit the current applicability of this
finding.
The true impact of pharmaceutical care ac-
tivities is still largely unknown. A review of
published pharmaceutical care research6 con-
cluded that few studies had evaluated the 
impact of pharmaceutical care in defined pop-
ulations. Deficiencies among the published lit-
erature include the need for quality research
design and a clear description of the pharma-
ceutical care process so that the impact could
be properly evaluated. The growth of DM ac-
tivites represents a shift in focus that may as-
sist pharmacists in addressing some of the de-
ficiencies noted in the pharmaceutical care
literature. While pharmaceutical care stresses
the optimization of outcomes in single patients,
DM attempts to improve outcomes in the over-
all population by structured interventions
aimed at patients with specific diseases. The
framework provided by DM programs may 
enable more pharmacists to participate and ef-
fectively improve outcomes through educa-
tion, patient targeting, and structured inter-
vention. The application of DM techniques may
serve to increase the efficiency and impact of
pharmacist intervention in targeted disease
states.
Studies suggest that the potential impact of
pharmacist intervention may be significant. In
a well-publicized modeling study, Johnson and
Bootman7 calculated the annual cost of drug-
related morbidity and mortality at $76.6 billion.
In a follow-up study, Johnson and Bootman8
estimated that pharmacist intervention and
pharmaceutical care could reduce the annual
expense of drug misadventure by $45.6 billion,
or 59.6% of the total expenditure. This reduc-
tion in costs is despite the fact that the model
assumed pharmacists would be paid an addi-
tional $10 for every patient encounter. In fact,
the model was insensitive to pharmacists’ fees,
with the overall cost savings only decreasing to
$44.7 billion if pharmacists were paid $40 per
patient encounter.
LEARNING FROM EXPERIENCE
The pharmacist’s role in different practice settings
Ambulatory care pharmacists as primary care
providers. With increasing healthcare costs, in-
creases in the number of available drugs and
time pressures facing physicians, pharmacists
emerged as a resource for managing diseases
that are highly dependent on pharmacother-
apy. The U.S. Indian Health Service (IHS) is
considered to be a forerunner in this move-
ment, by initiating pharmacist primary care
visits for minor illnesses in the 1960s.9 Today,
the IHS employs more than 500 pharmacists,
and offers a Clinical Pharmacy Training Pro-
gram (CPTP) that builds pharmacists’ skills in
the areas of medical history taking, laboratory
test interpretation, differential diagnosis, pa-
tient consultation, record review, and conflict
resolution.9 In addition, CPTP educates phar-
macists on the pathophysiology and pharma-
cotherapy of the 10 most prevalent diseases
within the IHS patient population.9 Within am-
bulatory care settings outside of the IHS, phar-
macist-managed clinics have emerged in the
areas of certain high-cost, chronic conditions
(e.g., asthma, diabetes, hypertension, HIV, car-
diovascular disease).
As the fields of DM and outcomes research
became more defined, health services re-
searchers began to study the impact of utiliz-
ing the pharmacist in this alternative role. In
1992, Kaiser Permanente and the University of
Southern California began a study measuring
the impact of three alternative models of phar-
macist consultation on the use and cost of
health care services: (1) consultation about new
or changed prescriptions as mandated by state
law, (2) consultation focused on selected high-
risk ambulatory patients, and (3) a control
model that maintained the standard of phar-
macy practice prior to the November 1992 Cal-
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ifornia regulations (mandating pharmacist 
consultation).10 Data was collected on health
status, satisfaction, and healthcare resource uti-
lization. They concluded that counseling pa-
tients on their medications might be unlikely
to reduce medication costs or the cost of office
visits, but may reduce the likelihood of hospi-
tal admissions and the overall costs of health-
care services.11
In 1995, at Cedars–Sinai Health System in
California, the health services research group
developed a pharmacist–physician comanage-
ment approach to providing healthcare in one
of their medical groups. This approach pro-
vided pharmacists the opportunity to not only
counsel patients on their disease, medications,
and overall care plan, but also began develop-
ing a comanagement approach to delivering
care with the physicians. The pharmacists pre-
sented the patient assessment to the physician
and made recommendations for therapeutic
adjustments based on evidence-based guide-
lines.
The researchers developed a randomized
comparative DM trial to measure the impact
of this approach for hypertension patient
management, which compared a pharmacist–
physician comanagement approach to deliver-
ing care with a physician alert approach (e.g.,
notifying a physician that a patient’s blood
pressure is out of control). Overall, the phar-
macist–physician comanagement approach im-
proved clinical outcomes (sustained blood
pressure reduction) and economic outcomes
(decreased per member per month costs) be-
yond that of the physician alert group.12 These
results prompted Cedars-Sinai to offer this ser-
vice to all hypertension patients, as well as nine
additional disease states.
Industry pharmacists as disease management and
outcomes research specialists. A growing area of
interest for pharmacists has been pursuing the
disciplines of DM and outcomes research
within the pharmaceutical industry. Due to the
increasing need for economic justification of
pharmaceutical products, the pharmaceutical
industry has developed extensive in house ex-
pertise in the areas of DM, outcomes research,
health economics, and pharmacoeconomics.13
The pharmaceutical industry uses this exper-
tise to determine the value of medical inter-
ventions.
Evidence of pharmacists’ interest in industry
opportunities is seen in the growth of advanced
pharmacoeconomics and outcomes research
training opportunities. Many pharmaceutical
companies have established 1–2-year fellow-
ship programs in which fellows have the op-
portunity to develop expertise in these disci-
plines by working alongside key researchers in
these fields. These types of programs offer
healthcare professionals the opportunity to
gain insight into these fields from both the
provider and industry perspective.
Community pharmacists as specialists in phar-
maceutical care. The pharmaceutical care move-
ment has also expanded into the community
pharmacy setting. Since community pharma-
cists are centrally located and easily accessible,
they are well positioned for this new role. Ad-
ditionally, with automated dispensing and pre-
scription margins decreasing, retail pharma-
cists are looking for alternative roles and new
sources of revenue. Some large retail chains re-
modeled stores in preparation of this new
movement, whereas others developed inde-
pendent patient counseling centers where no
dispensing actually takes place.
Retail chains are facilitating change from a
clerk–customer relationship to healthcare
provider–patient relationship by encouraging
pharmacists to provide pharmaceutical care.
However, the key to gaining acceptance and
sustaining this new role is to demonstrate the
pharmacist’s value through collecting out-
comes in terms that healthcare decision mak-
ers understand.
There are studies currently underway to im-
plement these newer models of care. Some of
the large retail chains have been very proactive
in leading this movement. For example, Wal-
greens now offers four Care Management Pro-
grams in the areas of asthma, H. pylori, dia-
betes, and coronary artery disease (CAD).14 In
addition, CVS has established Health Connec-
tions centers in certain stores to deliver health
information and management programs.
Another example is Eckerd, which has re-
cently begun testing a few different models of
community pharmacists implementing phar-
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maceutical care. In 1997, Eckerd began remod-
eling two of their stores in Atlanta, Georgia. In
hopes of freeing up pharmacist time to spend
with their patients, they reoriented the phar-
macies with technological enhancements to 
automate about 50% of the pharmacy’s dis-
pensing. To complement these enhancements,
patient consultation rooms were added specif-
ically for pharmacist–patient medication coun-
seling. This model would essentially allow for
pharmacists within local stores to differentiate
themselves—some as dispensing pharmacists
and others as pharmaceutical care pharma-
cists.15 Additionally, in 1998, Eckerd opened
the Eckerd Patient Care Center in Largo,
Florida. This model is exclusively dedicated to
patient counseling; no dispensing takes place
on the premises. At this site, patients make ap-
pointments to meet with the pharmacists for
education and review of their pharmaceutical
care plans. Eckerd used these new models of
care as a laboratory to collect outcomes data
and validate whether they are, in fact, improv-
ing patient care.16
Pharmacists’ involvement in specific disease
management efforts
Typically, DM programs are developed for
high-cost, chronic disease states. In the next few
paragraphs, examples of pharmacist involve-
ment in the disease states of asthma, hyper-
tension, and diabetes will be reviewed.
Asthma. Asthma is a prevalent disorder af-
fecting an estimated one in 25 million Ameri-
cans, and over $6 billion is spent annually to
treat this disease.18 However, it is estimated
that 40% of these costs are potentially avoided
through better asthma management.17 Phar-
macists dispense more than 7 million prescrip-
tions annually to treat asthma. These frequent
patient encounters place pharmacists in a
unique position to improve the outcomes of
asthma patients. The National Asthma and Ed-
ucation Program has recognized the potential
of pharmacist intervention and has created a
guide that describes the role of the pharmacist
in asthma care.18 Pharmacist responsibilities
delineated in this guide are described in Table
1. These guidelines provide an excellent frame-
work for defining the pharmacist’s role in
asthma DM.
An asthma DM program may assist phar-
macists in structuring their efforts in managing
asthma. Hunter and Bryant19 developed an ed-
ucational intervention targeted at pediatric
asthma patients and their parents. When sur-
veyed prior to the intervention, only 14% of
participants indicated that they were coun-
seled by a pharmacist about the safe and ef-
fective use of asthma medications. More than
half (58%) felt they needed more information
to effectively manage asthma, and 79% felt
that, if they received more information, their
child’s illness would be better managed or con-
trolled. All participants participated in the ed-
ucational intervention that consisted of a 45-
minute presentation, a demonstration of drug
delivery devices, and a question/answer/dis-
cussion session for participants to ask ques-
tions and share their experiences on handling
difficult situations. After the intervention,
100% of participants replied that they had
enough information to safely and effectively
use asthma medications.
While it is encouraging to observe educa-
tional efforts by pharmacists reflected in im-
proved survey ratings by patients, does this 
enhanced understanding lead to improved 
patient outcomes? A study of a pharmacist-
managed asthma program evaluated the im-
pact of attending a special asthma clinic on pa-
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TABLE 1. NATIONAL ASTHMA EDUCATION PROGRAM
GUIDELINES FOR PHARMACIST RESPONSIBILITIES IN
ASTHMA DISEASE MANAGEMENT
1. Educate patients about the role of each
medication.
2. Instruct patients about the proper techniques for
inhaling medications.
3. Monitor medication use and refill intervals to
help identify patients with poorly controlled
asthma.
4. Encourage patients purchasing nonprescription
asthma inhalers or tablets to seek medical care.
5. Help patients use peak-flow meters
appropriately.
6. Help patients discharged from the hospital after
an asthma exacerbation to understand their
asthma management plan.
Data from National Asthma Education and Preven-
tion Program.18
tients with frequent asthma exacerbations lead-
ing to emergency room (ER) utilization.20 Sub-
jects were eligible for the study if they were
seen in the ER a minimum of three times in a
12-month period. Twenty-five patients were
enrolled and attended the asthma clinic. Fre-
quency of asthma clinic visits were determined
by the severity of the patients’ illness and 
the patients’ perceived understanding of the
control of their illness. Other aspects of the pro-
gram included regular telephone contact be-
tween patient and pharmacist and an open-
door clinic policy. Results of the program were
encouraging. The 25 patients enrolled in the
study visited the ER 92 times in the 6 months
prior to study enrollment (47 times in the same
6 months of the year prior to the study). Dur-
ing the study period, there were only six ER
visits for asthma exacerbations. Despite the cost
of operating the clinic, the program resulted in
significant cost savings. The program saved
from $30,683 (based on baseline ER utilization
of 47 visits) to $68,393 (based on 92 baseline vis-
its).
Hypertension. Unlike asthma, which can be
characterized by frequent exacerbations, hy-
pertension is a largely asymptomatic disease.
As with other asymptomatic diseases, patients
are often noncompliant with therapy. This pre-
sents a challenge for healthcare practitioners
since chronic uncontrolled hypertension can
lead to sequelae such as stroke and heart at-
tacks. However, the literature offers many en-
couraging examples of successful hypertension
management programs. A controlled, random-
ized study was conducted in a retail pharmacy
chain store.21 Patients were recruited if they
were receiving antihypertensive medication or
had a blood pressure greater than 140/90 mm
Hg. Twenty-seven patients were enrolled as in-
tervention patients and 26 as control patients.
Intervention patients participated in four
scheduled monthly visits during which they re-
ceived drug therapy monitoring (heart rate,
blood pressure, medication history, compliance
monitoring, drug interactions screening, and
adverse drug effects screening) and patient ed-
ucation. Control patients received traditional
pharmacy services, which were defined as
screening for prescribing errors, prescription
filling, limited patient education (i.e., drug reg-
imen, potential side effects), and monitoring
patient-volunteered adverse drug reactions. At
the end of the 4-month study, results showed
that blood pressure control was significantly
improved in the study group. Medication com-
pliance rates also improved in the study group,
as well as the quality-of-life (Health Status
Questionnaire 2.0) scale of energy and fatigue.
Pharmacists are often needed to act as physi-
cian extenders in rural areas. A pilot study
evaluated the effectiveness of pharmacists in a
rural hypertension clinic.22 Prior to the study,
the pharmacists participated in an intensive
skill development program. Fifty-one patients
with controlled or uncontrolled hypertension
were randomized to either the pharmacist in-
tervention arm or the control arm of the study.
Intervention patients were scheduled to see the
pharmacist every 3–5 weeks. Blood pressure
and pulse were measured, and patients were
questioned regarding compliance, adverse
drug reactions, and understanding of present
drug regimens and lifestyle modifications.
Standardized patient education pamphlets
were distributed. The impact of the pharmacist
intervention was positive. Blood pressure was
reduced in the study group, a blinded peer re-
view panel deemed the appropriateness of the
blood pressure regimen to be significantly im-
proved, and the quality-of-life domains of
physical functioning, physical role limitations,
and bodily pain significantly improved. No sig-
nificant changes occurred in the control group.
Additionally, patient satisfaction scores were
significantly higher in the study group.
Although improved outcomes such as re-
duced blood pressure and improved quality of
life are desirable, economic outcomes must also
be examined given the increasing pressure on
financial resources within the health care sys-
tem. Interim results of an evaluation of a DM
program at Cedars–Sinai Health System dem-
onstrated that utilizing the pharmacist–physi-
cian comanagement approach to management
of hypertension may lead not only to improved
quality of care, but also to potential cost sav-
ings.23 Patients with uncontrolled hypertension
were randomized to an alert group, where the
primary care physician received a letter in-
forming him or her of the patient’s uncon-
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trolled status, or an intervention group. Inter-
vention patients were enrolled in a pharmacist
clinic where a pharmacist comanaged the pa-
tients with the physicians until blood pressure
goals were achieved. The interim results sug-
gest that both patients in the alert and inter-
vention groups had decreases in blood pres-
sure. However, blood pressure drops were
more substantial in the intervention group, de-
creasing from a baseline 157.7 mm Hg systolic
pressure to 148.9 mm Hg and 139.6 mm Hg, at
6 months and 1 year, respectively, when com-
pared with the alert group. The alert group de-
creasing from a baseline of 153.4 mm Hg to
151.7 mm Hg and 144.6 mm Hg, at 6 months
and 1 year, respectively. At 6 months, total cost
of treatment per member per month (PMPM)
increasing, mainly because of an increased
number of patient visits. At 1 year, however,
the costs of laboratory tests, office visits, and
medications decreased, resulting in average
savings of $6.40 PMPM.
Diabetes. In addition to asthma and hyper-
tension, pharmacists have also demonstrated a
positive impact in the management of diabetes.
Two studies24,25 evaluated the impact of phar-
macist management on outcomes in diabetes.
Jaber and colleagues examined the impact of
pharmacist-provided diabetes education, med-
ication counseling, and evaluation and adjust-
ment of the medication regimen in 39 non–in-
sulin-dependent diabetics (NIDDM) attending
a university-affiliated outpatient clinic. After 4
months, the patients who were managed by a
pharmacist were found to have significant im-
provements in hemoglobin A1c and fasting
plasma glucose. No changes in glycemic con-
trol were found in the control group, and no
changes were observed in either group for
blood pressure control, lipid profile, renal func-
tion, weight, or quality of life. The second study
compared a control group of diabetic patients
receiving standard pharmacist education to a
treatment group receiving additional small
group or individual supplementary education
for a 2-month period. As in the first study, the
intensive education improved outcomes. Pa-
tients in the treatment group had significantly
lower average weekly blood glucose levels and
a decreased incidence of hyperglycemic events.
Patients in the treatment group demonstrated
a significant increase in their understanding of
diabetes medications and blood glucose moni-
toring and a positive difference in their per-
ception and attitude towards diabetes and
communication with the pharmacist. This pos-
itive attitude toward communication with the
pharmacist could have a beneficial impact over
the course of a chronic disease.
Hyperlipidemia. According to the American
Heart Association approximately 99.5 million
Americans have blood cholesterol levels of 200
mg/d or higher.26 Lipid management is known
to reduce cardiovascular events, resulting in
the recent update of treatment guidelines by
the National Cholesterol Education Program
Expert Panel (NCEP).27 As a result of the new
guidelines, it is estimated that the number of
Americans who are candidates for cholesterol-
lowering medications will triple.28 This projec-
tion points to an increased need for pharmacist
involvement in lipid management.
Several studies have evaluated the effective-
ness of pharmacist-administered lipid manage-
ment programs. Ellis and colleagues examined
the effectiveness of pharmacist intervention in
the management of dyslipidemia among Vet-
erans Administration patients.29 They con-
ducted a prospective, randomized, controlled
trial involving 437 patients at nine VA medical
centers. Patients were randomized to either the
intervention group (were scheduled for fol-
low-up with an ambulatory care pharmacist)
or control group (received usual medical care).
Outcome goals were established using the pub-
lished guidelines, and costs were calculated us-
ing the VA Medical Center’s Decision Support
System. Results demonstrated that the inter-
vention group achieved a statistically signifi-
cant reduction in both total cholesterol and
low-density lipoprotein, compared to the con-
trol group.
A smaller study by Faulkner and colleagues
assessed the impact of pharmacist counseling
on compliance and effectiveness of lipid-low-
ering drugs.30 This study also employed a ran-
domized, controlled design but was aimed at
determining the effectiveness of pharmacist
telephone follow-up. The sample included 30
patients (15 intervention, 15 control) who had
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recently undergone coronary artery revascu-
larization at a university-affiliated hospital in
Omaha, Nebraska. Patients in the intervention
group were telephoned by a pharmacist once a
week for 12 weeks to emphasize the impor-
tance of lipid-lowering therapy, assess refills,
and identify potential issues related to compli-
ance (drug cost, side effects, overall well-be-
ing). Results showed that the intervention pro-
vided no short-term benefit during the first 12
weeks of therapy, but compliance and lipid-
lowering results were better in the intervention
group in the long-term (measured 2 years after
the start of therapy). Although these results
provided mixed evidence surrounding the ef-
fectiveness of the intervention, the study sug-
gests that pharmacist telephone follow-up may
be useful, particularly when in-person clinic
visits are impractical or impossible (e.g., in
rural areas or in medical centers that do not
have space or funding for a pharmacist-run
clinic).
Carson investigated the effectiveness of
pharmacist consultation notes added to the
charts of hyperlipidemic patients. Patients
were low-income adults receiving treatment at
a medicine clinic that is affiliated with a health
center in a depressed area of Albany, New
York.31 NCEP II guidelines served as the basis
for identifying risk factors and recommended
treatment regimens. An observational, single-
group design was employed in which a cohort
of primary and secondary prevention patients
were followed for use of risk-reducing med-
ications. Results demonstrated an increase in
the number of patients prescribed lipid-lower-
ing therapy during the study period, compared
to baseline.32 Although clinical outcome mea-
sures such as cholesterol and/or lipoprotein
levels were not discussed, findings suggest that
pharmacist chart notes may help to increase
physician compliance with guidelines for pre-
scribing lipid-lowering therapies.
An earlier study by Bogden and colleagues
measured the impact of a pharmacist–physi-
cian team on the ability to reach lipid-lowering
goals.33 The setting was a university-affiliated
medicine clinic in Honolulu, Hawaii. A single-
blind, randomized, controlled design was used
to compare those receiving the intervention to
a control group receiving usual care. The in-
tervention consisted of routine pharmacist–
patient consultations, including recommenda-
tions on dosage, appropriate drug treatments,
and monitoring. NCEP guidelines were used to
guide the appropriate initiation of therapy, as
well as to set lipid-lowering goals. Results re-
vealed that twice as many intervention patients
reached their lipid-lowering goals compared to
patients in the usual care group.
A LEGISLATIVE MILESTONE 
FOR PHARMACISTS
In July 1998, a legislative milestone was
reached for pharmacists. The approval of a
Medicaid waiver granted reimbursement for
pharmacists providing DM services in the state
of Mississippi. Under this legislation, pharma-
cists with appropriate training can be reim-
bursed for providing cognitive services for pa-
tients with diabetes, asthma, lipid disorders,
and anticoagulation under patient-specific
treatment protocols approved by a physician.
In order to qualify as a provider under the
waiver, pharmacists must be credentialed in
each of the therapeutic areas included. The re-
quirements for reimbursement under this law
are provided in Table 2.
In response to this legislation and the need
for pharmacists across the country to receive
advanced training to qualify as DM providers
for independently run programs, the National
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TABLE 2. REQUIREMENTS FOR PHARMACIST
REIMBURSEMENT UNDER THE
MISSISSIPPI MEDICAID WAIVER
1. The pharmacist must complete a credentialing
program that is approved by the state Board of
Pharmacy.
2. The pharmacist must obtain a written referral
from the patient’s physician.
3. The pharmacy at which the credentialed
pharmacist practices must have a private
counseling area.
4. A record of services provided to the patient must
be maintained in the pharmacy.
5. The pharmacist must obtain a provider number
from the state Medicaid department.
Data from National Association of Boards of Phar-
macy.34
Association of Boards of Pharmacy (NABP),
American Pharmaceutical Association (APhA),
National Association of Chain Drug Stores
(NACDS), and the National Community Phar-
macists’ Association (NCPA) collaborated to
form the National Institute for Standards in
Pharmocist Credentialing (NISPC). NISPC cur-
rently offers pharmacists certifications in the ar-
eas of asthma, diabetes, and anti-coagulation.35
THE FUTURE: GROWTH OF DISEASE
MANAGEMENT WITHIN 
COMMUNITY PHARMACIES
Although the advanced training that is cur-
rently being delivered will assist all pharmacists
in delivering pharmaceutical care, some feel that
the greatest potential may very well lie within
the “corner drugstore.” Several factors render
this setting desirable for the provision of DM
services. These factors are related to the dy-
namics of community pharmacy practice: pa-
tient access, consistency between sites, data col-
lection mechanisms, and rising drug costs.
Dynamics of pharmacy practice
Within the community, pharmacists practice
at the interface of care and therefore have the
ability to interact with consumers and patients.
Public opinion polls reveal that pharmacists are
consistently ranked among the most trusted
professionals.36 Figure 2 illustrates the drug
prescribing process in relation to the organiza-
tions that currently offer DM. Because phar-
macists, similarly to physicians, have the abil-
ity to directly deliver DM services, they have
the ability to serve as conduits for implement-
ing programs developed by health insurance
providers, pharmacy benefit managers, phar-
maceutical companies, wholesalers and dis-
tributors, and employers. It is important to note
that this figure is restricted in focus to the pre-
scribing process and does not depict the roles
that other allied health professionals play in de-
livering DM.
Patient access
In addition to existing at the interface, com-
munity pharmacies offer virtually open access
to patients. There are presently more than
50,000 pharmacies in the United States (Table
3) and more than 128,000 pharmacists practic-
ing at these sites.37 Most stores are open at least
6 days per week, and many now offer 24-hour
prescription services. Furthermore, there are no
appointments or insurance preapprovals re-
quired in order to receive one-on-one profes-
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FIG. 2. The prescribing process empowers pharmacists to deliver pharmaceutical disease management. Ovals il-
lustrate the infrastructure in which pharmacists and physicians practice (e.g., group or clinic for physicians and cor-
porate chain for pharmacists).
sional consultations with the pharmacist. 
Finally, patients who are receiving chronic
medications are likely to visit their pharmacy
regularly in order to obtain refills, with the ex-
ception of certain conditions for which insur-
ers may allow extended days’ supply. Overall,
the community pharmacy is a convenient loca-
tion for health and DM program implementa-
tion.
Consistency between sites
Another attractive characteristic that is
unique to chain pharmacies is an ability to ad-
minister a program at multiple stores. This is
an important attribute for programs targeted at
large or geographically dispersed patient pop-
ulations because it provides the infrastructure
required for implementation. Moreover, ad-
ministering a single program over multiple
sites allows for consistency that enhances the
credibility of results.
There are also some practical benefits to
implementing DM within a pharmacy chain.
For example, administrative approval need
only be sought from one party, data may be
obtained from a single repository, and there
is likely to be a process in place for commu-
nicating with the sites. In addition, the struc-
tural layout of the stores may be similar,
which could be important if a patient coun-
seling area is required for delivering the pro-
gram.
Data collection mechanisms
In contrast to many other segments of health-
care, the data collection capability of commu-
nity pharmacies is advanced. Because data 
capture and processing are functional require-
ments of community pharmacies, most systems
are prompt and reliable. An electronic record
(consisting primarily of patient demographics
and prescription history) is maintained for each
patient. While these data are currently quite
limited in scope, it is likely that advances in
technology will allow for greater connectivity
between the patient’s pharmacy and medical
encounters.
Increasing drug costs
In the face of the most dramatic increase in
drug costs in history, one cannot discount the
possibility that attention will be drawn to phar-
macies as an intervention point to optimize uti-
lization. In recent years prescription drug
spending has risen about 15–20% per year38,39
and is expected to continue to increase.40 Ac-
cording to industry analysts, drugs accounted
for 11–14% of total healthcare expenditures in
1998, which represents a 7% increase from the
early 1990s.39 Although the management of
drug costs alone does not qualify as DM, it is
likely that insurers and employers will attempt
to manage drug costs as a part of broader ini-
tiatives.
CONCLUSION
The profession of pharmacy has undergone
dramatic changes over the past decade. The
DM movement, along with technological im-
provements in prescription processing, has al-
lowed pharmacists to focus on patient care.
Pharmacists in a variety of practice settings are
participating in DM and are beginning to dem-
onstrate their value in the management of sev-
eral high-cost diseases, including asthma, hy-
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TABLE 3. U.S. PHARMACY DEMOGRAPHICS, 
EXCLUDING MAIL ORDER FACILITIES, 1998
Type of pharmacy Number of stores Prescription volume (1998)
Traditional chain 19,638 1.08 billion
Independents 19,717 721 million
Food/drug stores 6,838 310 million
Mass merchandisers 4,931 284 million
Total 51,124 2.4 billion
Data from National Association of Chain Drug Stores.37
pertension, poststroke anticoagulation, and di-
abetes.
It has been estimated that traditional pre-
scription processing utilizes only about 10% of
the technologic potential computers have to 
offer pharmacists.41 As pharmacists become
more involved in managing chronic diseases,
expanding technology will enhance their ef-
forts. Software applications to assist pharma-
cists in DM have been developed and will con-
tinue to be improved. Ultimately, pharmacy
information systems will support the processes
of drug dispensing, prescription processing,
and the task of outcomes data collection, doc-
umentation, and monitoring.42
In addition, the advanced clinical training
provided by pharmacy schools, major health-
care providers, and accrediting bodies will bet-
ter equip pharmacists with the knowledge and
skills required to contribute to DM. Although
most pharmacists’ DM contributions to date
have been made in ambulatory care and in-
dustry settings, it is anticipated that DM will
continue to grow within organizations con-
cerned with health management. It is essential
that outcomes data surrounding these activities
be collected in order to continue to substanti-
ate the value of pharmacists’ contributions to
patient care through DM.
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